For people with type 1 diabetes, tight glycemic control, accomplished by intensive insulin therapy, reduces the risk of developing late-diabetic complications. 1,2 The consequence of intensive insulin therapy is a 3-fold increase in the number of hypoglycemic events. These adverse effects are fatal in severe cases, and thus are of great concern, leading to potential lack of compliance with intensive insulin therapy. 3,4 Self-monitoring of blood glucose (SMBG) has become the standard approach of glucose monitoring. However, SMBG provides only a snapshot of the glycemic control throughout the day with typically 3-4 preprandial measurements. Consequently, SMBG misses postprandial, overnight, and other glucose variabilities, making it vulnerable as a method for identifying episodes of hypoglycemia. Professional continuous glucose monitoring (PCGM) technologies, on the other hand, measure interstitial glucose (IG) every 1-5 minutes and gives a much better insight into the patient's glucose profile. PCGM is prescribed to the patient so that he or she can monitor IG typically over a short course of 3-5 days. With such a high temporal glucose resolution, episodes of hypoglycemia could be identified by the patient in consultation with a clinician so as to develop a management strategy for adjusting glucose-regulating factors, such as insulin, carbohydrate intake, and exercise to avoid hypoglycemia. PCGM technology utilizes a sensor with a glucoseoxidase-enzyme-containing material placed in the subcutaneous tissue of the abdomen, thigh, or upper arm. Glucose 511744D STXXX10.